Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4966 AL 4980

Effects of Gingko biloba supplementation in Alzheimer's disease patients receiving cholinesterase inhibitors: data from the ICTUS study

Canevelli M, Adali N, Kelaiditi E, Cantet C, Ousset PJ, Cesari M; ICTUS/DSA Group.

Phytomedicine. 2014 May 15;21(6):888-92. doi: 10.1016/j.phymed.2014.01.003. Epub 2014 Feb 16.

D-amino acid-based peptide inhibitors as early or preventative therapy in Alzheimer disease

Kumar J, Sim V.

Prion. 2014 Jan-Feb;8(1):119-24. doi: 10.4161/pri.28220.

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan R, Vassar R.

Lancet Neurol. 2014 Mar;13(3):319-29. doi: 10.1016/S1474-4422(13)70276-X. Epub 2014 Feb 17.

Metal protein attenuating compounds for the treatment of Alzheimer's dementia

Sampson EL, Jenagaratnam L, McShane R.

Cochrane Database Syst Rev. 2014 Feb 21;2014(2):CD005380. doi: 10.1002/14651858.CD005380.pub5.

Why calcium channel blockers could be an elite choice in the treatment of Alzheimer's disease: a comprehensive review of evidences

Saravanaraman P, Chinnadurai RK, Boopathy R.

Rev Neurosci. 2014;25(2):231-46. doi: 10.1515/revneuro-2013-0056.

Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease

Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P.

Curr Drug Targets. 2014 May;15(5):539-50. doi: 10.2174/1389450115666140226112321.

Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies

Brondino N, Re S, Boldrini A, Cuccomarino A, Lanati N, Barale F, Politi P.

ScientificWorldJournal. 2014 Jan 22;2014:174282. doi: 10.1155/2014/174282. eCollection 2014.

Retinoids as potential targets for Alzheimer's disease

Sodhi RK, Singh N.

Pharmacol Biochem Behav. 2014 May;120:117-23. doi: 10.1016/j.pbb.2014.02.016. Epub 2014 Feb 26.

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions

Adler G, Mueller B, Articus K.

Int J Clin Pract. 2014 Apr;68(4):465-70. doi: 10.1111/ijcp.12374. Epub 2014 Mar 3.

Harnessing the immune system for treatment and detection of tau pathology

Congdon EE, Krishnaswamy S, Sigurdsson EM.

J Alzheimers Dis. 2014;40 Suppl 1(0):S113-21. doi: 10.3233/JAD-132435.

Alzheimer's disease prevention & acetyl salicylic acid: a believable story

Pomponi M, Pomponi MF.

Indian J Med Res. 2014 Jan;139(1):1-3.

Amyloid-ß-directed immunotherapy for Alzheimer's disease

Lannfelt L, Relkin NR, Siemers ER.

J Intern Med. 2014 Mar;275(3):284-95. doi: 10.1111/joim.12168.

Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study

Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S.

Int Clin Psychopharmacol. 2014 Jul;29(4):216-23. doi: 10.1097/YIC.0000000000000032.

The translocator protein as a drug target in Alzheimer's disease

Chua SW, Kassiou M, Ittner LM.

Expert Rev Neurother. 2014 Apr;14(4):439-48. doi: 10.1586/14737175.2014.896201.

Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review)

Cai Z.

Mol Med Rep. 2014 May;9(5):1533-41. doi: 10.3892/mmr.2014.2040. Epub 2014 Mar 11.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias